AI derived decision-making and assessment in CAD
Free Online Sponsored webinar | SCCT
Thursday, March 20 | 12noon – 1pm EST
Join us for a FREE online webinar featuring Armin Zadeh, MD, MSCCT; Michael Blaha, MD, MPH; Dinesh Kalra, MD, FSCCT and Irfan Shafique, MD discussing DeepVessel FFRCT, AI plaque analysis, and biomarkers in risk stratification, diagnosis, predicting acute coronary syndrome and management of CAD.
Speaker and Panelists:
Irfan Shafique, MD | Moderator
Armin Zadeh, MD, MSCCT
Michael Blaha, MD, MPH
Dinesh Kalra, MD, FSCCT
Sponsored by Keya Medical
About DEEPVESSEL FFR
DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). The software processes coronary CTA images semi-automatically, generates a three-dimensional model of the coronary artery tree, and estimates CT FFR values. DEEPVESSEL FFR is FDA-Cleared, CE-Marked, NMPA-Cleared, HSA-Certified.
About Keya Medical
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers of excellence in Beijing, Shanghai, Shenzhen, and Seattle. Follow us on LinkedIn, Twitter, and Facebook.
Media Contact
contact@keyamedna.com
Learn more about DEEPVESSEL FFR
We are actively looking for clinical partners in the United States and EMEA.